UnknownPhase 4NCT03521063

Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.

Studying Bronchopulmonary dysplasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hospital Central "Dr. Ignacio Morones Prieto"
Principal Investigator
RAUL H ROQUE SANCHEZ, MD, MD
Hospital Central "Dr. Ignacio Morones Prieto"
Intervention
Budesonide(drug)
Enrollment
108 enrolled
Eligibility
All sexes
Timeline
20182019

Study locations (1)

Collaborators

Universidad Autonoma de San Luis Potosí

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03521063 on ClinicalTrials.gov

Other trials for Bronchopulmonary dysplasia

Additional recruiting or active studies for the same condition.

See all trials for Bronchopulmonary dysplasia

← Back to all trials